Analyst Consensus ?
ConsensusHold18 ratings
Bullish844.4%
Neutral1055.6%
Bearish00.0%
1 unmapped firm rating excluded from the percentages.
Mettler-Toledo International Inc. · MTD · FY2026 Q3 · Calendar Q4 2026
Mettler-Toledo raises growth outlook after Q3 strength led by China
Mettler-Toledo's Q3 results and raised outlook indicate continued demand across key markets, particularly China, while automation and digitalization are strategic growth avenues. The durability of China demand and the ability to manage costs and uneven end-market conditions remain central tests.
Why did MTD rise 4.8% after beating EPS estimates in FY2026 Q3?
Research this report with FN2. Free to start; review your question before sending.
Reported After market closeNYSEHealthcare
$33.64B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$12.57
Consensus $12.13
EPS surprise
+3.6%
Reported versus consensus
Reported revenue
$1.09B
Consensus $1.07B
Revenue surprise
+2.1%
Reported versus consensus
Market reaction
event-close to next-session close
Stock move
+4.8%
Event window
SPY move
+0.8%
Same window
Abnormal move
+3.9%
Stock minus SPY
Volume
0.5×
Versus trailing sessions
Subsequent drift
0.0%
Up to 20 sessions
MTDSPY benchmark
Ask FN2 about MTD FY2026 Q3
Choose a question to continue your research
Why did MTD rise 4.8% after beating EPS estimates in FY2026 Q3?What changed in MTD's guidance and outlook in FY2026 Q3?Give me the bull and bear case for MTD after FY2026 Q3 earnings.
Free to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.
Transcript intelligence
What changed
Q3 revenue and adjusted EPS grew year over year, with 13% organic sales growth in China, according to the call analysis. Management raised its FY2026 and 2027 outlook to approximately 5% local-currency sales growth. Compared with Q2, growth continued, though the reported revenue-growth rate was lower; both quarters featured raised guidance.
Guidance delta
Raised: the supplied Q3 analysis says management raised FY2026 and 2027 guidance to approximately 5% local-currency sales growth. No further guidance detail is included here.
Key takeaways
- Q3 revenue was $1.1 billion, up 6% year over year; adjusted EPS was $12.57, up 13%.
- China delivered 13% organic sales growth, led by industrial and laboratory demand.
- Management highlighted AI-enabled X-ray image recognition, the ACT305 weighing transmitter and LabX integration as product and platform initiatives.
- Higher material and transportation costs, tariffs and tougher comparisons temper the outlook.
Management priorities
- Continue the Spinnaker sales program and expand LabX integration.
- Develop automation and digitalization products, including AI-enabled X-ray image recognition.
- Strengthen supply-chain agility and resilience.
- Pursue demand in China, emerging markets, pharma and biotech, and semiconductors.
Follow MTD with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$1,765.3Current
$1,100Low
$1,437.25Average
$1,700High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 6, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Oct 13, 2026 |
| Barclays | Overweight | Overweight | Maintain | Oct 7, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Aug 3, 2026 |
| Stifel | Buy | Buy | Maintain | Aug 3, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Aug 3, 2026 |
| Jefferies | Buy | Buy | Maintain | Jul 31, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | May 11, 2026 |
| Baird | Neutral | Neutral | Maintain | May 11, 2026 |
| Citigroup | Buy | Buy | Maintain | May 8, 2026 |
| B of A Securities | Neutral | Neutral | Maintain | Sep 22, 2025 |
| UBS | Buy | Neutral | Upgrade | May 20, 2025 |
| Goldman Sachs | Neutral | Neutral | Maintain | Jul 9, 2024 |
| CFRA | Hold | Hold | Maintain | May 8, 2020 |
| Bank of America | Neutral | Buy | Downgrade | Jan 3, 2019 |
| Deutsche Bank | Hold | Hold | Maintain | May 4, 2018 |
| Cantor Fitzgerald | Buy | Buy | Maintain | Jul 28, 2014 |
| Credit Agricole | Outperform | Underperform | Upgrade | Feb 7, 2013 |
| CL King | Neutral | Buy | Downgrade | Dec 19, 2012 |
| ISI Group | Underweight | Upgrade | Jul 27, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $1,765.3. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Morgan Stanley | Analyst unavailable | $1,575 | $1,560.98 | -10.8% | Oct 12, 2026 |
| Barclays | Analyst unavailable | $1,700 | $1,533.07 | -3.7% | Oct 7, 2026 |
| RBC Capital | Dan Leonard | $1,515 | $1,405.14 | -14.2% | Sep 1, 2026 |
| Morgan Stanley | Kallum Titchmarsh | $1,450 | $1,433.89 | -17.9% | Aug 4, 2026 |
| Barclays | Analyst unavailable | $1,575 | $1,416.3 | -10.8% | Aug 3, 2026 |
| Stifel Nicolaus | Daniel Arias | $1,600 | $1,416.3 | -9.4% | Aug 3, 2026 |
| Jefferies | Analyst unavailable | $1,580 | $1,412.91 | -10.5% | Jul 31, 2026 |
| Evercore ISI | Analyst unavailable | $1,350 | $1,292.74 | -23.5% | Jul 6, 2026 |
| Stifel Nicolaus | Daniel Arias | $1,400 | $1,031.64 | -20.7% | May 18, 2026 |
| Robert W. Baird | Analyst unavailable | $1,194 | $1,124.46 | -32.4% | May 11, 2026 |
| Barclays | Analyst unavailable | $1,500 | $1,345.89 | -15.0% | Apr 14, 2026 |
| Morgan Stanley | Kallum Titchmarsh | $1,475 | $1,382.72 | -16.4% | Feb 9, 2026 |
| Robert W. Baird | Catherine Ramsey Schulte | $1,445 | $1,373.57 | -18.1% | Feb 9, 2026 |
| Wells Fargo | Analyst unavailable | $1,450 | $1,393.64 | -17.9% | Dec 15, 2025 |
| Susquehanna | Analyst unavailable | $1,600 | $1,393.64 | -9.4% | Dec 15, 2025 |
| Barclays | Analyst unavailable | $1,550 | $1,393.64 | -12.2% | Dec 15, 2025 |
| Goldman Sachs | Analyst unavailable | $1,475 | $1,381.37 | -16.4% | Dec 9, 2025 |
| Morgan Stanley | Kallum Titchmarsh | $1,550 | $1,468.09 | -12.2% | Dec 1, 2025 |
| Evercore ISI | Analyst unavailable | $1,400 | $1,345.27 | -20.7% | Oct 7, 2025 |
| Barclays | Analyst unavailable | $1,350 | $1,289.82 | -23.5% | Oct 2, 2025 |
| Barclays | Analyst unavailable | $1,325 | $1,185.18 | -24.9% | Jun 24, 2025 |
| UBS | Dan Leonard | $1,350 | $1,159.1 | -23.5% | May 19, 2025 |
| Jefferies | Tycho Peterson | $1,100 | $1,100.01 | -37.7% | May 4, 2025 |
| Robert W. Baird | Analyst unavailable | $1,034 | $1,003.16 | -41.4% | Apr 22, 2025 |
| Stifel Nicolaus | Daniel Arias | $1,450 | $1,378.34 | -17.9% | Nov 11, 2024 |
| Stifel Nicolaus | Daniel Arias | $1,550 | $1,441.43 | -12.2% | Aug 5, 2024 |
| Robert W. Baird | Catherine Schulte | $1,375 | $1,441.43 | -22.1% | Aug 5, 2024 |
| Jefferies | Tycho Peterson | $1,250 | $1,404.09 | -29.2% | Jun 3, 2024 |
| Stifel Nicolaus | Daniel Arias | $1,510 | $1,510.25 | -14.5% | May 13, 2024 |
| Robert W. Baird | Catherine Schulte | $1,360 | $1,449.38 | -23.0% | May 13, 2024 |
| Stifel Nicolaus | Daniel Arias | $1,500 | $1,195.02 | -15.0% | Sep 6, 2022 |
| UBS | Elizabeth Garcia | $1,237 | $1,349.73 | -29.9% | Jul 31, 2022 |
| Wells Fargo | Analyst unavailable | $1,410 | $1,284.63 | -20.1% | Apr 25, 2022 |
Track every rating change on MTD the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationMettler-Toledo International Inc. (MTD) is a global enterprise dedicated to the production and provision of precision instruments and related services. The company's operations are strategically organized across five geographical divisions: its domestic U.S. market, Swiss operations, Western European activities, Chinese operations, and an 'Other' segment covering remaining territories. Their extensive product portfolio serves diverse scientific and industrial needs. Within the laboratory sphere, Mettler-Toledo supplies a comprehensive array of equipment, including high-precision balances, advanced liquid handling systems (such as pipetting solutions), automated laboratory reactors, titrators, pH meters, sensors and analyzers for process analytics, instruments for evaluating physical properties, thermal analysis systems, and various other analytical tools. These hardware offerings are complemented by LabX, their proprietary software platform designed for managing and analyzing instrument-generated data.…
Historical context
All MTD earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| MRNA Moderna, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +7.3% | Moderna raises 2026 outlook as vaccines and oncology advance |
| ELAN Elanco Animal Health Incorporated | FY2026 Q3 · Calendar Q4 2026 | — | +6.2% | Elanco lifts 2026 outlook as innovation products drive Q3 growth |
| GMAB Genmab A/S | FY2026 Q3 · Calendar Q4 2026 | +55.6% | -4.3% | Genmab pairs nine-month growth with a heavier launch agenda |
| NTRA Natera, Inc. | FY2026 Q3 · Calendar Q4 2026 | -49.3% | -15.2% | Natera raises 2026 revenue outlook as Signatera drives Q3 growth |
| STE STERIS plc | FY2027 Q2 · Calendar Q4 2026 | +9.7% | +2.5% | STERIS raises FY2027 EPS outlook after 9% revenue growth |
| BDX Becton, Dickinson and Company | FY2026 Q4 · Calendar Q4 2026 | +2.0% | +2.1% | BD FY2026: Broad Growth, With FY2027 Margin and Alaris Risks |
Latest beats and misses
Who reports nextBeat on EPS
- FNFFY2026 Q3 · November 5, 20260.0% EPS+6.6% move
- IAGFY2026 Q3 · November 5, 2026+16.7% EPS+4.6% move
- GMABFY2026 Q3 · November 5, 2026+55.6% EPS-4.3% move
- STEFY2027 Q2 · November 4, 2026+9.7% EPS+2.5% move
- IRMFY2026 Q3 · November 5, 2026+4.6% EPS-11.1% move
- AFRMFY2027 Q1 · November 5, 2026+23.8% EPS+1.9% move
Missed on EPS
- VMRKFY2026 Q3 · November 4, 2026-425.6% EPS+2.4% move
- NTRAFY2026 Q3 · November 5, 2026-49.3% EPS-15.2% move
- TIGOFY2026 Q3 · November 5, 2026-40.8% EPS+2.6% move
- UHALFY2027 Q2 · November 4, 2026-15.4% EPS-3.2% move
- LAMRFY2026 Q3 · November 5, 2026-3.6% EPS-0.8% move
- CMIFY2026 Q3 · November 5, 2026-6.0% EPS-4.9% move
Get the MTD recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-11-06T17:15:23.203653+00:00
- FN2 earnings calendar · 2026-11-06T01:23:16.275024+00:00
- Polygon adjusted daily market bars · 2026-11-06T17:30:44.085306+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-06T17:30:44.081506+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-06. For educational purposes only; not investment advice.